Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;13(1):9.
doi: 10.21037/atm-24-182. Epub 2025 Feb 25.

GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?

Kathleen Boyle  1 , Kimberly J Perez  1   2
Affiliations
Editorial

GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer?

Kathleen Boyle et al. Ann Transl Med. .
No abstract available

Keywords: Pancreatic adenocarcinoma (PDAC); gemcitabine (GEM); paclitaxel.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-24-182/coif). K.J.P. reports one-time advisory board honoraria with Ipsen, Exelixis, and Novartis. The other author has no conflicts of interest to declare.

Comment on

References

    1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. 10.1056/NEJMoa1011923 - DOI - PubMed
    1. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-81. 10.1016/S0140-6736(23)01366-1 - DOI - PMC - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. 10.1056/NEJMoa1304369 - DOI - PMC - PubMed
    1. Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019;108:78-87. 10.1016/j.ejca.2018.12.007 - DOI - PubMed
    1. Imperial R, Mosalem O, Majeed U, et al. Second-Line Treatment of Pancreatic Adenocarcinoma: Shedding Light on New Opportunities and Key Talking Points from Clinical Trials. Clin Exp Gastroenterol 2024;17:121-34. 10.2147/CEG.S390655 - DOI - PMC - PubMed